Bio-Rad Laboratories, Inc(NYSE:BIO)

Latest On Bio-Rad Laboratories, Inc (BIO):

Updated on: March 18, 2021

Date/Time	Type	Description	Signal
2023-05-16 11:05 EST	News	Bio-Rad And Its Real Value	N/A
2023-05-04 22:53 EST	News	Bio-Rad Labs Non-GAAP EPS of $3.34 misses by $0.14, revenue of $676.8M misses by $12.48M	N/A
2023-05-04 22:53 EST	News	Bio-Rad Laboratories, Inc. (BIO) Q1 2023 Earnings Call Transcript	N/A
2023-05-03 21:36 EST	News	Bio-Rad Labs Q1 2023 Earnings Preview	N/A
2023-04-13 18:09 EST	News	Bio-Rad: Aggressively Buying In FY 2023	N/A

About Bio-Rad Laboratories, Inc (BIO):

Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universiti read more...es and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

See Advanced Chart

General

Name Bio-Rad Laboratories, Inc
Symbol BIO
Type Common Stock
Exchange NYSE
Currency USD
Country USA
SectorHealthcare
IndustryMedical Devices
Full Time Employees 8,000
Last Split Factor2:1
Last Split Date2002-03-08
Fiscal Year EndDecember
IPO Date1966-01-01
Gic SectorHealth Care
Gic GroupPharmaceuticals, Biotechnology & Life Sciences
Gic IndustryLife Sciences Tools & Services
Gic SubIndustryLife Sciences Tools & Services
Web URLhttp://www.bio-rad.com

Valuation

Trailing PE 4.52
Forward PE 55.25
Price/Sales (Trailing 12 Mt.) 6.71
Price/Book (Most Recent Quarter) 1.71
Enterprise Value Revenue 6.41
Enterprise Value EBITDA 3.22

Financials

Most Recent Quarter 2020-12-31
Current Year EPS Estimate $11.44
Next Year EPS Estimate $12.26
Next Quarter EPS Estimate $2.92
Profit Margin 150%
Operating Margin 16%
Return on Assets 2%
Return on Equity 49%
Revenue 2.55 billion
Earnings Per Share $126.20
Revenue Per Share $85.52
Gross Profit 1.44 billion
Quarterly Earnings Growth 26.5%

Highlights

Market Capitalization 17.19 billion
EBITDA 546.86 million
PE Ratio -7.05
PEG Ratio 1.19
Analyst Target Price $752.5
Book Value Per Share $331.05

Share Statistics

Shares Outstanding 24.77 million
Shares Float 21.33 million
% Held by Insiders 1436%
% Held by Institutions 79.6%
Shares Short 685323
Shares Short Prior Month 551816
Short Ratio 2.66
Short % of Float 3%
Short % of Shares Outstanding 2%

Technicals

Beta 0.8
52 Week High $689
52 Week Low $309.38
50 Day Moving Average 595.18
200 Day Moving Average 569.61

Dividends

Dividend Date N/A
ExDividend Date N/A
Dividend Yield 0%

ESG Rating

Rating Date 2019-01-01
ESG Score 23.57
Environment Score 6.03
Social Score 16.8
Governance Score 10.75
Controversy Level 2

Bio-Rad Laboratories, Inc (BIO) Dividend Calendar:

Show entries

Search:

Ex-Dividend Date	Payment Date	Record Date	Declared Date	Amount
No data available in table

Showing 0 to 0 of 0 entries

Bio-Rad Laboratories, Inc (BIO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.

Show entries

Quarter Date	Report Date	Actual Revenue	Reported EPS	EPS Estimate	Deviation from Estimate
2020-12-31	2021-02-11	$N/A	$4.01	$3.32	20.9%
2020-09-30	2020-10-29	$N/A	$3.00	$1.82	64.86%
2020-06-30	2020-07-30	$N/A	$1.61	$1.15	40.27%
2020-03-31	2020-05-06	$N/A	$1.91	$1.57	22.04%
2019-12-31	2020-02-13	$624.43 million	$2.32	$2.45	-5.11%
2019-09-30	2019-10-31	$560.63 million	$1.61	$1.41	14.59%
2019-06-30	2019-08-01	$572.62 million	$1.57	$1.34	17.1%
2019-03-31	2019-05-08	$553.98 million	$1.65	$1.09	50.99%
2018-12-31	2019-02-28	$616.85 million	$2.13	$1.73	22.89%
2018-09-30	2018-11-01	$545.14 million	$0.91	$1.14	-20.03%

Bio-Rad Laboratories, Inc (BIO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:

Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares

Cash Flow:

Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures

Balance Sheet:

Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Bio-Rad Laboratories, Inc (BIO) Chart:

Bio-Rad Laboratories, Inc (BIO) News:

Below you will find a list of latest news for Bio-Rad Laboratories, Inc (BIO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Bio-Rad Laboratories, Inc (BIO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date:

Options Type:

Moneyness:

Show entries

Search:

Expiration Date	Strike	Last Price	Type	Volume	Open Interest	Implied Volatility	In the Money	Change	Change Percent
2025-04-17	165	0	CALL	0	0	114.09	TRUE	0	0
2025-04-17	170	0	CALL	0	0	105.08	TRUE	0	0
2025-04-17	175	0	CALL	0	0	98.25	TRUE	0	0
2025-04-17	180	0	CALL	0	0	89.48	TRUE	0	0
2025-04-17	185	0	CALL	0	0	88.75	TRUE	0	0
2025-04-17	190	0	CALL	0	0	85.57	TRUE	0	0
2025-04-17	195	0	CALL	0	0	80.7	TRUE	0	0
2025-04-17	200	0	CALL	0	0	80.23	TRUE	0	0
2025-04-17	210	0	CALL	0	0	73.46	TRUE	0	0
2025-04-17	220	0	CALL	0	0	67.34	TRUE	0	0
2025-04-17	230	20.7	CALL	0	0	66.34	FALSE	0	0
2025-04-17	240	3.62	CALL	1	1	53.21	FALSE	-3.11	-0.46
2025-04-17	250	3.5	CALL	0	12	55.12	FALSE	0	0
2025-04-17	260	1.52	CALL	1	3	63.76	FALSE	1.52	0
2025-04-17	270	3.78	CALL	0	2	85.81	FALSE	0	0
2025-04-17	280	2.2	CALL	0	3	97.33	FALSE	0	0
2025-04-17	290	3.36	CALL	0	2	108.06	FALSE	0	0
2025-04-17	300	0	CALL	0	0	118.14	FALSE	0	0
2025-04-17	310	0	CALL	0	0	127.64	FALSE	0	0
2025-04-17	320	0	CALL	0	0	136.65	FALSE	0	0

Latest BIO Trades:

Date	Shares	Price
Jun 13, 2022 7:59 PM EST	9	$482.27
Jun 13, 2022 7:59 PM EST	9	$482.27
Jun 13, 2022 7:59 PM EST	10	$481.93
Jun 13, 2022 7:59 PM EST	1	$481.75
Jun 13, 2022 7:59 PM EST	10	$481.68

Bio-Rad Laboratories, Inc (BIO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Form Type:

Show entries

Search:

Date	Form Type	View
2020-10-30	10-Q (Quarterly report [Sections 13 or 15(d)])
2020-10-29	8-K (Current report)
2020-09-15	4 (Statement of changes in beneficial ownership of securities)
2020-09-14	4 (Statement of changes in beneficial ownership of securities)
2020-09-14	4 (Statement of changes in beneficial ownership of securities)
2020-09-14	4 (Statement of changes in beneficial ownership of securities)
2020-09-14	4 (Statement of changes in beneficial ownership of securities)
2020-09-09	4 (Statement of changes in beneficial ownership of securities)
2020-09-09	4 (Statement of changes in beneficial ownership of securities)
2020-09-09	4 (Statement of changes in beneficial ownership of securities)
2020-09-09	4 (Statement of changes in beneficial ownership of securities)
2020-09-09	4 (Statement of changes in beneficial ownership of securities)
2020-09-09	4 (Statement of changes in beneficial ownership of securities)
2020-09-09	4 (Statement of changes in beneficial ownership of securities)
2020-09-08	4 (Statement of changes in beneficial ownership of securities)
2020-09-08	4 (Statement of changes in beneficial ownership of securities)
2020-09-08	4 (Statement of changes in beneficial ownership of securities)
2020-09-08	4 (Statement of changes in beneficial ownership of securities)
2020-09-08	4 (Statement of changes in beneficial ownership of securities)
2020-09-08	4 (Statement of changes in beneficial ownership of securities)

Bio-Rad Laboratories, Inc (BIO) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Bio-Rad Laboratories, Inc (BIO). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1436%
Institutional Ownership: 7960%

Show entries

Search:

Transaction Date	Insider Name	Insider Title	Type	Shares Number	Shares Price	Total Transaction	Shares Held After Transaction
2020-09-11	Giovanni Magni	EVP, Chief Strategy Officer	Buy	500.00	139.56	69,780.00	22,561.00
2020-09-11	Giovanni Magni	EVP, Chief Strategy Officer	Buy	500.00			22,743.00
2020-09-11	NORMAN D SCHWARTZ	Chairman, President, and CEO	Buy	3,200.00			299,834.00
2020-09-11	Michael Crowley	EVP, GBL Commercial Operations	Buy	600.00			4,341.00
2020-09-11	ANNETTE TUMOLO	Executive Vice President	Buy	600.00			4,420.35
2020-09-11	RONALD W HUTTON	Vice President and Treasurer	Buy	150.00			4,740.29
2020-09-10	Giovanni Magni	EVP, Chief Strategy Officer	Buy	400.00	160.37	64,148.00	22,030.00
2020-09-10	Giovanni Magni	EVP, Chief Strategy Officer	Buy	500.00	215.98	107,990.00	22,267.00
2020-09-10	Giovanni Magni	EVP, Chief Strategy Officer	Buy	371.00	333.34	123,669.14	22,369.00
2020-09-10	Giovanni Magni	EVP, Chief Strategy Officer	Buy	500.00	326.15	163,075.00	22,410.00
2020-09-08	Giovanni Magni	EVP, Chief Strategy Officer	Buy	400.00			21,829.00
2020-09-07	TIMOTHY S ERNST	EVP, General Counsel & Sec	Buy	500.00			1,959.80
2020-09-07	NORMAN D SCHWARTZ	Chairman, President, and CEO	Buy	3,000.00			298,122.00
2020-09-07	Michael Crowley	EVP, GBL Commercial Operations	Buy	600.00			4,039.00
2020-09-07	ANNETTE TUMOLO	Executive Vice President	Buy	600.00			4,118.35
2020-09-07	RONALD W HUTTON	Vice President and Treasurer	Buy	170.00			4,649.29
2020-09-05	TIMOTHY S ERNST	EVP, General Counsel & Sec	Buy	500.00			1,632.80
2020-09-05	Giovanni Magni	EVP, Chief Strategy Officer	Buy	500.00			21,677.00
2020-09-05	Michael Crowley	EVP, GBL Commercial Operations	Buy	600.00			3,665.00
2020-09-05	ANNETTE TUMOLO	Executive Vice President	Buy	600.00			3,765.35

Bio-Rad Laboratories, Inc

(NYSE:BIO)

$333.62

STRONG BUY

Latest On Bio-Rad Laboratories, Inc (BIO):

About Bio-Rad Laboratories, Inc (BIO):

General

Valuation

Financials

Highlights

Share Statistics

Technicals

Dividends

ESG Rating

Bio-Rad Laboratories, Inc (BIO) Dividend Calendar:

Bio-Rad Laboratories, Inc (BIO) Earnings History:

Bio-Rad Laboratories, Inc (BIO) Company Financial Statements:

Income Statement:

Cash Flow:

Balance Sheet:

Bio-Rad Laboratories, Inc (BIO) Chart:

Bio-Rad Laboratories, Inc (BIO) News:

Bio-Rad Laboratories, Inc (BIO) Options:

Latest BIO Trades:

Bio-Rad Laboratories, Inc (BIO) SEC Filings:

Bio-Rad Laboratories, Inc (BIO) Insider Transactions: